Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -64.51 Million EUR | 23.57% |
| 2022 | -99.39 Million EUR | -141.49% |
| 2021 | -46.86 Million EUR | -3.4% |
| 2020 | -46.11 Million EUR | -548.31% |
| 2019 | 9.71 Million EUR | -29.77% |
| 2018 | 12.84 Million EUR | 95.78% |
| 2017 | 3.64 Million EUR | 909.8% |
| 2016 | -31.47 Million EUR | 26.77% |
| 2015 | 9.76 Million EUR | 88.95% |
| 2014 | -9.18 Million EUR | 12.56% |
| 2013 | -13.35 Million EUR | -69.41% |
| 2012 | -7.68 Million EUR | -635.15% |
| 2011 | 795 Thousand EUR | 82.23% |
| 2010 | -6.07 Million EUR | -46.73% |
| 2009 | -4.7 Million EUR | -116.79% |
| 2008 | -1.82 Million EUR | 39.63% |
| 2007 | -3.01 Million EUR | -662.01% |
| 2006 | 605 Thousand EUR | -42.26% |
| 2005 | 998 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -21.79 Million EUR | 9.81% |
| 2024 Q1 | -22.35 Million EUR | -28.46% |
| 2023 Q2 | -18.06 Million EUR | -10.7% |
| 2023 Q4 | -24.44 Million EUR | -10.78% |
| 2023 Q3 | -22.06 Million EUR | -22.13% |
| 2023 FY | - EUR | 23.57% |
| 2023 Q1 | -16.32 Million EUR | 70.93% |
| 2022 Q4 | -56.14 Million EUR | -160.18% |
| 2022 Q1 | -18.4 Million EUR | -110.44% |
| 2022 FY | - EUR | -141.49% |
| 2022 Q3 | 93.29 Million EUR | 165.42% |
| 2022 Q2 | -142.61 Million EUR | -674.7% |
| 2021 Q2 | -53.83 Million EUR | -129.45% |
| 2021 Q3 | -160.2 Million EUR | -197.58% |
| 2021 Q4 | 176.33 Million EUR | 210.07% |
| 2021 FY | - EUR | -3.4% |
| 2021 Q1 | -23.46 Million EUR | -7596.17% |
| 2020 Q4 | 313 Thousand EUR | 101.19% |
| 2020 Q3 | -26.27 Million EUR | -23.82% |
| 2020 Q2 | -21.22 Million EUR | -976.9% |
| 2020 FY | - EUR | -548.31% |
| 2020 Q1 | 2.42 Million EUR | -36.67% |
| 2019 Q4 | 3.82 Million EUR | 38.64% |
| 2019 Q1 | 9.44 Million EUR | 17.15% |
| 2019 Q2 | -5.65 Million EUR | -159.84% |
| 2019 Q3 | 2.75 Million EUR | 148.76% |
| 2019 FY | - EUR | -29.77% |
| 2018 Q1 | 4.9 Million EUR | 196.0% |
| 2018 FY | - EUR | 95.78% |
| 2018 Q4 | 8.06 Million EUR | 1983.2% |
| 2018 Q3 | 387 Thousand EUR | -70.3% |
| 2018 Q2 | 1.3 Million EUR | -73.41% |
| 2017 Q1 | 3.37 Million EUR | 869.86% |
| 2017 FY | - EUR | 909.8% |
| 2017 Q4 | -5.1 Million EUR | -235.53% |
| 2017 Q3 | 3.76 Million EUR | -10.61% |
| 2017 Q2 | 4.21 Million EUR | 24.94% |
| 2016 Q1 | 41 Thousand EUR | -99.49% |
| 2016 FY | - EUR | 26.77% |
| 2016 Q4 | -438 Thousand EUR | 63.44% |
| 2016 Q3 | -1.19 Million EUR | -131.8% |
| 2016 Q2 | 3.76 Million EUR | 9087.8% |
| 2015 Q3 | 214 Thousand EUR | 104.05% |
| 2015 Q4 | 8.02 Million EUR | 3648.13% |
| 2015 FY | - EUR | 88.95% |
| 2015 Q2 | -5.28 Million EUR | -404.58% |
| 2015 Q1 | -1.04 Million EUR | 77.6% |
| 2014 FY | - EUR | 12.56% |
| 2014 Q4 | -4.67 Million EUR | -507.14% |
| 2014 Q3 | 1.14 Million EUR | 255.98% |
| 2014 Q2 | -736 Thousand EUR | 75.49% |
| 2014 Q1 | -3 Million EUR | -42.25% |
| 2013 Q3 | -6.16 Million EUR | -87.64% |
| 2013 FY | - EUR | -69.41% |
| 2013 Q1 | -1.51 Million EUR | -5.35% |
| 2013 Q2 | -3.28 Million EUR | -116.55% |
| 2013 Q4 | -2.11 Million EUR | 65.75% |
| 2012 Q4 | -1.44 Million EUR | -4.2% |
| 2012 Q3 | -1.38 Million EUR | 0.0% |
| 2012 FY | - EUR | -635.15% |
| 2011 FY | - EUR | 82.23% |
| 2010 FY | - EUR | -46.73% |
| 2009 FY | - EUR | -116.79% |
| 2008 FY | - EUR | 39.63% |
| 2007 FY | - EUR | -662.01% |
| 2006 FY | - EUR | -42.26% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -1861.003% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 51.566% |
| Adocia SA | -22.73 Million EUR | -183.816% |
| Aelis Farma SA | -6.34 Million EUR | -916.496% |
| Biophytis S.A. | -13.8 Million EUR | -367.379% |
| Advicenne S.A. | -6.24 Million EUR | -933.264% |
| genOway Société anonyme | 6.35 Million EUR | 1115.896% |
| IntegraGen SA | -52.5 Thousand EUR | -122782.502% |
| Medesis Pharma S.A. | -3.84 Million EUR | -1577.996% |
| Neovacs S.A. | -8.44 Million EUR | -663.556% |
| NFL Biosciences SA | -4.04 Million EUR | -1493.287% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 89052.158% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -2145.257% |
| Sensorion SA | -22.31 Million EUR | -189.135% |
| Theranexus Société Anonyme | -7.38 Million EUR | -773.358% |
| TME Pharma N.V. | -5.07 Million EUR | -1172.023% |
| Valbiotis SA | -6.95 Million EUR | -827.635% |
| TheraVet SA | -517.33 Thousand EUR | -12371.005% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -241.071% |
| argenx SE | -199.5 Million EUR | 67.662% |
| BioSenic S.A. | -6.79 Million EUR | -849.338% |
| Celyad Oncology SA | -7.76 Million EUR | -731.083% |
| DBV Technologies S.A. | -79.53 Million EUR | 18.878% |
| Galapagos NV | 51.03 Million EUR | 226.412% |
| Genfit S.A. | -28.05 Million EUR | -129.999% |
| GeNeuro SA | -14.31 Million EUR | -350.61% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -330.688% |
| Innate Pharma S.A. | -7.57 Million EUR | -751.372% |
| Inventiva S.A. | -101.84 Million EUR | 36.654% |
| MaaT Pharma SA | -19.74 Million EUR | -226.834% |
| MedinCell S.A. | -20.04 Million EUR | -221.845% |
| Nanobiotix S.A. | -34.01 Million EUR | -89.65% |
| Onward Medical N.V. | -35.23 Million EUR | -83.11% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -1355.263% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -177.302% |
| Oxurion NV | -16.72 Million EUR | -285.66% |
| Pharming Group N.V. | 4.98 Million EUR | 1395.271% |
| Poxel S.A. | -12.17 Million EUR | -429.74% |
| GenSight Biologics S.A. | -21.73 Million EUR | -196.903% |
| Transgene SA | -27.02 Million EUR | -138.74% |
| Financière de Tubize SA | 184.57 Thousand EUR | 35055.112% |
| UCB SA | 1.26 Billion EUR | 105.084% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | -127.549% |